Niacin

Generic Name: Niacin

Brand Names: Advicor, Concept Ob, Irospan 24/6 Kit, Mvc-fluoride, Niacor, Niaspan, Niodan, Simcor, Vitafol-one

Drug Type: Small Molecule

Chemical Formula: C_₆H_₅NO_₂

CAS Number: 59-67-6

Unique Ingredient Identifier: 2679MF687A

Background: Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.

Indication: Niacin is indicated to prevent vitamin deficiencies in pediatric and adult patients receiving parenteral nutrition as part of multivitamin intravenous injections. Niacin oral tablets are indicated as a monotherapy or in combination with simvastatin or lovastatin to treat primary hyperlipidemia and mixed dyslipidemia. It can also be used to reduce the risk of nonfatal myocardial infarctions in patients with a history of myocardial infarction and hyperlipidemia. Niacin is also indicated with bile acid binding resins to treat atherosclerosis in patients with coronary artery disease and hyperlipidemia or to treat primary hyperlipidemia. Finally niacin is indicated to treat severe hypertriglyceridemia.

Associated Conditions: Atherosclerosis, High Cholesterol, High Triglyceride Level, Mixed Dyslipidemias, Nonfatal Myocardial Infarction, Pellagra, Primary Hypercholesterolemia, Severe Hypertriglyceridemia (sHTG), Type II Hyperlipidaemia

Associated Therapies: Dietary supplementation

Clinical Trials

A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED)

Phase 1

Completed

Conditions: Hypercholesterolemia

First Posted Date: 2008-10-08

Last Posted Date: 2019-11-21

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 26

Registration Number: NCT00769132

Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study

Phase 2

Completed

Conditions: Dyslipidemia

Interventions: Drug: Atorvastatin
Drug: ABT335
Drug: ER Niacin

First Posted Date: 2008-08-06

Last Posted Date: 2016-02-29

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 25

Registration Number: NCT00728910

Locations: 🇺🇸
CTRC (Clinical Translational Research Center), Philadelphia, Pennsylvania, United States

Evaluate Carotid Artery Plaque Composition by Magnetic Resonance Imaging in People Receiving Cholesterol Medication

Phase 4

Completed

Conditions: Coronary Artery Disease
Carotid Artery Diseases
Atherosclerosis

Interventions: Drug: Atorvastatin
Drug: Placebo Niacin
Drug: Niacin
Drug: Placebo Colesevelam
Drug: Colesevelam

First Posted Date: 2008-07-15

Last Posted Date: 2022-06-07

Lead Sponsor: University of Washington

Target Recruit Count: 217

Registration Number: NCT00715273

Locations: 🇺🇸
University of Washington Coronary Atherosclerosis Research Lab, Seattle, Washington, United States
🇺🇸
St. Luke's Idaho Cardiology, Boise, Idaho, United States
🇺🇸
Yakima Heart Center, Yakima, Washington, United States

and more 1 locations

Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT)

Phase 4

Conditions: Dyslipidemia
Atherosclerosis

Interventions: Drug: simvastatin
Drug: Nicotinic Acid

First Posted Date: 2008-07-09

Last Posted Date: 2011-07-22

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 200

Registration Number: NCT00712049

Locations: 🇦🇹
Medical University Vienna, Vienna, Austria

Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)

Phase 4

Completed

Conditions: Peripheral Arterial Disease

Interventions: Drug: Ezetimibe
Drug: Niaspan
Drug: Statin therapy
Behavioral: Standard care
Drug: Aspirin
Drug: Placebo Niaspan
Drug: Placebo Ezetimibe
Drug: Clopidogrel
Procedure: Percutaneous transluminal angioplasty (PTA)